Invention Grant
- Patent Title: Methods, compositions and devices for treating cancer with illudofulvenes
-
Application No.: US17508729Application Date: 2021-10-22
-
Publication No.: US12023339B2Publication Date: 2024-07-02
- Inventor: Michael Kelner
- Applicant: AF Chemicals, LLC
- Applicant Address: US CA San Diego
- Assignee: AF Chemicals, LLC
- Current Assignee: AF Chemicals, LLC
- Current Assignee Address: US CA San Diego
- Agency: SCI-LAW STRATEGIES, PC
- Priority: EP 214360 2019.12.09
- Main IPC: A61K31/5375
- IPC: A61K31/5375 ; A61K31/047 ; A61K31/121 ; A61K31/122 ; A61K31/135 ; A61K31/15 ; A61K31/16 ; A61K31/18 ; A61K31/192 ; A61K31/198 ; A61K31/351 ; A61K31/357 ; A61K31/401 ; C12Q1/6886
Abstract:
In an embodiment of the invention, a method of treating cancer includes screening to select a patient population that will respond to an Illudofulvene Analog composition based on the presence of one or more Transcription Coupled Repair (TCR) mutations, deletions or other events interfering with TCR biomarker expression in combination with upregulation of Myc and/or PTGR biomarker expression and treating the patient population with the Illudofulvene Analog composition.
Information query
